Literature DB >> 34843679

Characterization of the CpG Island Hypermethylated Phenotype Subclass in Primary Melanomas.

Kathleen Conway1, Yihsuan S Tsai2, Sharon N Edmiston2, Joel S Parker3, Eloise A Parrish2, Honglin Hao4, Pei Fen Kuan5, Glynis A Scott6, Jill S Frank7, Paul Googe8, David W Ollila9, Nancy E Thomas10.   

Abstract

Cutaneous melanoma can be lethal even if detected at an early stage. Epigenetic profiling may facilitate the identification of aggressive primary melanomas with unfavorable outcomes. We performed clustering of whole-genome methylation data to identify subclasses that were then assessed for survival, clinical features, methylation patterns, and biological pathways. Among 89 cutaneous primary invasive melanomas, we identified three methylation subclasses exhibiting low methylation, intermediate methylation, or hypermethylation of CpG islands, known as the CpG island methylator phenotype (CIMP). CIMP melanomas occurred as early as tumor stage 1b and, compared with low-methylation melanomas, were associated with age at diagnosis ≥65 years, lentigo maligna melanoma histologic subtype, presence of ulceration, higher American Joint Committee on Cancer stage and tumor stage, and lower tumor-infiltrating lymphocyte grade (all P < 0.05). Patients with CIMP melanomas had worse melanoma-specific survival (hazard ratio = 11.84; confidence interval = 4.65‒30.20) than those with low-methylation melanomas, adjusted for age, sex, American Joint Committee on Cancer stage, and tumor-infiltrating lymphocyte grade. Genes hypermethylated in CIMP compared with those in low-methylation melanomas included PTEN, VDR, PD-L1, TET2, and gene sets related to development/differentiation, the extracellular matrix, and immunity. CIMP melanomas exhibited hypermethylation of genes important in melanoma progression and tumor immunity, and although present in some early melanomas, CIMP was associated with worse survival independent of known prognostic factors.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34843679      PMCID: PMC9135958          DOI: 10.1016/j.jid.2021.11.017

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   7.590


  76 in total

1.  Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer.

Authors:  Andrew E Teschendorff; Usha Menon; Aleksandra Gentry-Maharaj; Susan J Ramus; Daniel J Weisenberger; Hui Shen; Mihaela Campan; Houtan Noushmehr; Christopher G Bell; A Peter Maxwell; David A Savage; Elisabeth Mueller-Holzner; Christian Marth; Gabrijela Kocjan; Simon A Gayther; Allison Jones; Stephan Beck; Wolfgang Wagner; Peter W Laird; Ian J Jacobs; Martin Widschwendter
Journal:  Genome Res       Date:  2010-03-10       Impact factor: 9.043

2.  CpG island methylator phenotype predicts progression of malignant melanoma.

Authors:  Atsushi Tanemura; Alicia M Terando; Myung-Shin Sim; Anneke Q van Hoesel; Michiel F G de Maat; Donald L Morton; Dave S B Hoon
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

3.  Increasing burden of melanoma in the United States.

Authors:  Eleni Linos; Susan M Swetter; Myles G Cockburn; Graham A Colditz; Christina A Clarke
Journal:  J Invest Dermatol       Date:  2009-01-08       Impact factor: 8.551

4.  Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis.

Authors:  Qing Xue; Zhihong Lin; You-Hong Cheng; Chiang-Ching Huang; Erica Marsh; Ping Yin; Magdy P Milad; Edmond Confino; Scott Reierstad; Joy Innes; Serdar E Bulun
Journal:  Biol Reprod       Date:  2007-07-11       Impact factor: 4.285

Review 5.  Adjuvant Therapy of Melanoma.

Authors:  Diwakar Davar; John M Kirkwood
Journal:  Cancer Treat Res       Date:  2016

6.  Estrogen receptor expression in cutaneous melanoma: a real-time reverse transcriptase-polymerase chain reaction and immunohistochemical study.

Authors:  Vincenzo de Giorgi; Carmelo Mavilia; Daniela Massi; Alessia Gozzini; Palma Aragona; Annalisa Tanini; Serena Sestini; Milena Paglierani; Vieri Boddi; Maria Luisa Brandi; Torello Lotti
Journal:  Arch Dermatol       Date:  2009-01

7.  Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort.

Authors:  Jérémie Nsengimana; Jon Laye; Anastasia Filia; Christy Walker; Rosalyn Jewell; Joost J Van den Oord; Pascal Wolter; Poulam Patel; Antje Sucker; Dirk Schadendorf; Göran B Jönsson; D Timothy Bishop; Julia Newton-Bishop
Journal:  Oncotarget       Date:  2015-05-10

8.  β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.

Authors:  Jérémie Nsengimana; Jon Laye; Anastasia Filia; Sally O'Shea; Sathya Muralidhar; Joanna Poźniak; Alastair Droop; May Chan; Christy Walker; Louise Parkinson; Joanne Gascoyne; Tracey Mell; Minttu Polso; Rosalyn Jewell; Juliette Randerson-Moor; Graham P Cook; D Timothy Bishop; Julia Newton-Bishop
Journal:  J Clin Invest       Date:  2018-04-16       Impact factor: 14.808

9.  PITX1 protein interacts with ZCCHC10 to regulate hTERT mRNA transcription.

Authors:  Takahito Ohira; Hirotada Kojima; Yuko Kuroda; Sayaka Aoki; Daigo Inaoka; Mitsuhiko Osaki; Hideki Wanibuchi; Futoshi Okada; Mitsuo Oshimura; Hiroyuki Kugoh
Journal:  PLoS One       Date:  2019-08-12       Impact factor: 3.240

10.  A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data.

Authors:  Andrew E Teschendorff; Francesco Marabita; Matthias Lechner; Thomas Bartlett; Jesper Tegner; David Gomez-Cabrero; Stephan Beck
Journal:  Bioinformatics       Date:  2012-11-21       Impact factor: 6.937

View more
  1 in total

Review 1.  PTH, FGF-23, Klotho and Vitamin D as regulators of calcium and phosphorus: Genetics, epigenetics and beyond.

Authors:  Ignacio Portales-Castillo; Petra Simic
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.